Time-to-failure in 1st-line endocrine therapy with ER+/HER2-metastatic breast cancer

被引：0
|
作者：
Nishimura, S. [1 ]
Akiyoshi, S. [1 ]
Koga, C. [1 ]
Oikawa, M. [1 ]
Nskamura, Y. [1 ]
Ishida, M. [1 ]
Ohno, S. [1 ]
机构：
[1] Kyushu Natl Canc Ctr, Breast Oncol, Fukuoka, Japan
来源：
BREAST | 2015年 / 24卷
关键词：
D O I：
10.1016/S0960-9776(15)70209-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P168
引用
收藏
页码：S82 / S83
页数：2
相关论文
共 50 条
  • [1] Targeted therapies for ER+/HER2-metastatic breast cancer
    Yamamoto-Ibusuki, Mutsuko
    Arnedos, Monica
    Andre, Fabrice
    BMC MEDICINE, 2015, 13
  • [2] Vaginal and sexual health in patients with ER+/HER2-metastatic breast cancer (mBC)
    Shanahan, Kelly
    Sammons, Sarah
    Meisel, Jane L.
    Pluard, Timothy J.
    Kozlowski, Monica
    Carroll, Dominic
    Attias, Elizabeth
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2023, 30 (12): : 1296 - 1296
  • [3] OVERALL SURVIVAL IN POST-MENOPAUSAL WOMEN WITH HR+/HER2-METASTATIC BREAST CANCER TREATED WITH 1ST-LINE ENDOCRINE THERAPY VS. CHEMOTHERAPY
    Vekeman, F.
    Hao, Y.
    Cheng, W. Y.
    Fortier, J.
    Robitaille, M.
    Duh, M. S.
    VALUE IN HEALTH, 2015, 18 (03) : A194 - A195
  • [4] The Future of ER+/HER2-Metastatic Breast Cancer Therapy: Beyond PI3K Inhibitors
    Stravodimou, Athina
    Voutsadakis, Ioannis A.
    ANTICANCER RESEARCH, 2020, 40 (09) : 4829 - 4841
  • [5] Quantitative evaluation of the efficacy and safety profiles of two types of targeted inhibitors combined with endocrine therapy in ER+/HER2-metastatic breast cancer
    Pan, Meiyu
    Lin, Yan
    Liu, Yinhui
    Xu, Ruijuan
    Yang, Jin
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 80 (09) : 1387 - 1397
  • [6] Dose modifications of ribociclib and endocrine therapy for treatment of ER+ HER2− metastatic breast cancer
    Kristoffer B. Kristensen
    Ida Marie Nedergaard Thomsen
    Tobias Berg
    Annette R. Kodahl
    Anders Bonde Jensen
    Breast Cancer Research and Treatment, 2021, 188 : 799 - 809
  • [7] CISPLATIN AS 1ST-LINE THERAPY FOR METASTATIC BREAST-CANCER
    SLEDGE, GW
    LOEHRER, PJ
    ROTH, BJ
    EINHORN, LH
    JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (12) : 1811 - 1814
  • [8] Using real-world data to evaluate the performance of endocrine therapies in ER+/Her2-metastatic breast cancer patients.
    Chen, Tenghui
    Zhang, Zhaojie
    Gao, Lei
    Scholz, Catherine
    Gualberto, Antonio
    Yu, Lihua
    Yu, Kun
    CANCER RESEARCH, 2022, 82 (12)
  • [9] BUDGET IMPACT ANALYSIS OF EVEROLIMUS FOR ER+, HER2-METASTATIC BREAST CANCER PATIENTS IN THE UNITED STATES
    Xie, J.
    Diener, M.
    De, G.
    Wu, E. Q.
    Namjoshi, M.
    VALUE IN HEALTH, 2012, 15 (04) : A212 - A212
  • [10] Efficacy and safety of everolimus for heavily pretreated patients with ER+/HER2-metastatic breast cancer.
    Osako, Tomofumi
    Nishimura, Reiki
    Nishiyama, Yasuyuki
    Fujisue, Mamiko
    Yamada, Mitsuhiro
    Suko, Kyoko
    Morioka, Junko
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345